One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerA Randomized Clinical Trial
Thierry Conroy, MD; Florence Castan, MSc; Anthony Lopez, MD; et al.
doi : 10.1001/jamaoncol.2022.3829
November 2022, Vol 8, No. 11, Pages 1543-1704
Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
Per E. Lønning, MD, PhD; Oleksii Nikolaienko, PhD; Kathy Pan, MD; et al.
Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid CarcinomaA Nonrandomized Controlled Trial
Allen S. Ho, MD; Sungjin Kim, MS; Cynthia Zalt, MPH; et al.
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
Brittany L. Bychkovsky, MD, MSc; Nihat B. Agaoglu, MD, PhD; Carolyn Horton, MS; et al.
Short-term Outcomes of Laparoscopy-Assisted vs Open Surgery for Patients With Low Rectal CancerThe LASRE Randomized Clinical Trial
Wei-Zhong Jiang, MD; Jian-Min Xu, MD; Jia-Di Xing, MD; et al.
Association of QTc Formula With the Clinical Management of Patients With Cancer
Daniel R. Richardson, MD, MSc; P. Christopher Parish, BS; Xianming Tan, PhD; et al.
Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer
Kyung Hwan Kim, MD, PhD; Jaewon Oh, MD, PhD; Gowoon Yang, MD; Joongyo Lee, MD; Jihun Kim, PhD; Seo-yeon Gwak, MD;Iksung Cho, MD, PhD; Seung Hyun Lee, MD, PhD; Hwa Kyung Byun, MD, PhD; Hyo-Kyoung Choi, PhD;Jinsung Kim, PhD; Jee Suk Chang, MD, PhD; Seok-Min Kang, MD, PhD; Hong In Yoon, MD, PhD
Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With CancerA Systematic Review and Meta-analysis
Abdulhadi Jfri, MSc, MD; Rachel Meltzer, MPH, MD; Arash Mostaghimi, MPH, MD;Nicole LeBoeuf, MPH, MD; Lauren Guggina, MD
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With CancerPrimary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial
Robert Olson, MD; Will Jiang, MD; Mitchell Liu, MD; Alanah Bergman, PhD; Devin Schellenberg, MD; Benjamin Mou, MD;Abraham Alexander, MD; Hannah Carolan, MD; Fred Hsu, MD; Stacy Miller, MD; Siavash Atrchian, MD;Elisa Chan, MD; Clement Ho, MD; Islam Mohamed, MD; Angela Lin, MD; Tanya Berrang, MD; Andrew Bang, MD;Nick Chng, PhD; Quinn Matthews, PhD; Sarah Baker, MD; Vicky Huang, PhD; Ante Mestrovic, PhD;Derek Hyde, PhD; Chad Lund, MD; Howard Pai, MD; Boris Valev, MD; Shilo Lefresene, MD; Scott Tyldesley, MD
Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome
Omar H. Butt, MD, PhD; Alice Y. Zhou, MD, PhD; Paolo F. Caimi, MD; Patrick H. Luckett, PhD; Julie K. Wisch, PhD;Paul-Robert Derenoncourt, MD; Kenneth Lee, BS; Gregory F. Wu, MD, PhD; Marcos J. G. de Lima, MD; Jian L. Campian, MD, PhD;Matthew J. Frank, MD, PhD; John F. DiPersio, MD, PhD; Armin Ghobadi, MD; Beau M. Ances, MD, PhD
Changes in Opioid Prescriptions and Potential Misuse and Substance Use Disorders Among Childhood Cancer Survivors Following the 2016 Opioid Prescribing Guideline
Xin Hu, MSPH; Katharine E. Brock, MD, MS; Karen E. Effinger, MD, MS;Bo Zhang, PhD; Ilana Graetz, PhD; Joseph Lipscomb, PhD; Xu Ji, PhD
Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation
Garth W. Strohbehn, MD, MPhil; Robert Holleman, MPH; Jennifer Burns, MS; Mandi L. Klamerus, MPH;Michael J. Kelley, MD; Eve A. Kerr, MD, MPH; Nithya Ramnath, MBBS; Timothy P. Hofer, MD, MSc
Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018A SEER Population Data Analysis
Zhuo Ran Cai, MDMichael L. Chen, BAMartin A. Weinstock, MD, PhDYoun H. Kim, MDRoberto A. Novoa, MDEleni Linos, MD, DrPH
Evolution of Early-Phase Anticancer Drug Investigations in China
Shuhang Wang, MDYue Yu, MDYale Jiang, MDHuishan Zhang, MDPeiwen Ma, MDGang Liu, PhDNing Li, MD
Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer
the investigated variant of concern, with median inhibition ofMaximilian J. Mair, MDManfred Mitterer, MDPia Gattinger, PhDJulia M. BergerRudolf Valenta, MDDominic Fong, MDMatthias Preusser, MD
Identification of Deaths Caused by Cancer and COVID-19 in the US During March to December 2020
Xuesong Han, PhDXin Hu, MSPHJingxuan Zhao, MPHAhmedin Jemal, DVM, PhDK. Robin Yabroff, PhD
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast CancerCritical Analysis of Strengths, Weaknesses, and Misinterpretations
Fabio Conforti, MD; Laura Pala, MD; Vincenzo Bagnardi, PhD; Tommaso De Pas, MD; Marco Colleoni, MD;Marc Buyse, ScD, PhD; Gabriel Hortobagyi, MD, PhD; Luca Gianni, PhD; Eric Winer, MD, PhD;Sibylle Loibl, MD, PhD; Javier Cortes, MD, PhD; Martine Piccart, MD, PhD; Antonio C. Wolff, MD;Giuseppe Viale, PhD; Richard D. Gelber, PhD
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Aleix Prat, MD, PhD; Aditya Bardia, MD, MPH; Giuseppe Curigliano, MD, PhD; M. Elizabeth H. Hammond, MD;Sibylle Loibl, MD, PhD; Sara M. Tolaney, MD, MPH; Giuseppe Viale, MD
Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma
Binbin Zheng-Lin, MD, MSc; David M. Faleck, MD; James J. Harding, MD
Early Death After Chemotherapy as a Quality Indicator—Is It Time to Bench the Benchmark?
Catherine Dunn, MBBS; Lucy Gately, MBBS, PhD; Peter Gibbs, MBBS, MD
Ensuring High-Quality Shared Decision-making for Lung Cancer Screening
Robert J. Volk, PhD; Dawn Stacey, PhD
Misinterpretation of Surgeons’ Statements on Cancer Removal—The Adverse Effects of “We Got It All�
Bonnie O. Wong, MD, PhD; Justin T. Clapp, PhD, MPH; Arden M. Morris, MD, MPH
Keeping the Heartbeat Off-Target in Cancer Therapy
Benjamin N. Starobin, MD; Kevin F. Kwaku, MD, PhD
Pushing the Envelope for Active Surveillance
Andrea L. Merrill, MD; Priya H. Dedhia, MD, PhD
Defining a Therapeutic Ratio for Stereotactic Ablative Radiation Therapy in Oligometastatic Disease—Another Piece of the Puzzle
Matthew S. Katz, MD; Gregory A. Russo, MD
Hereditary Cancer Syndromes—A Broader Clinical Spectrum Than Previously Understood?
Susrutha Puthanmadhom Narayanan, MBBS; Yana G. Najjar, MD
Hereditary Cancer Syndromes—A Broader Clinical Spectrum Than Previously Understood?—Reply
Chenjie Zeng, PhD, MPH; Georgia L. Wiesner, MD, MS; Joshua C. Denny, MD, MS
Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases
Bin Zhang, MD; Shuixing Zhang, PhD
Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases—Reply
Debu Tripathy, MD; Sara M. Tolaney, MD; Mary Tagliaferri, MD
Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy
Ryan Sun, PhD; Lee-Jen Wei, PhD
Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy—Reply
Ran Jennifer Wei, PhD; Miguel Martin, MD, PhD; Stephen R. D. Johnston, MD, PhD
